A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2ep53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours

被引：0
|
作者：
Schoeffski, P. [1 ]
Lorusso, P. [2 ]
Yamamoto, N. [3 ]
Lugowska, I. [4 ]
Garcia, V. Moreno [5 ]
Lauer, U. [6 ,7 ]
Hu, C. [8 ]
Jayadeva, G. [9 ]
Lahmar, M. [10 ]
Gounder, M. [11 ]
机构：
[1] Univ Hosp Leuven, Dept Gen Med Oncol, Leuven Canc Inst, Leuven, Belgium
[2] Yale Sch Med, Yale Canc Ctr, New Haven, CT USA
[3] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan
[4] Maria Sklodowska Curie Natl Res Inst Oncol, Early Phase Clin Trials Unit, Warsaw, Poland
[5] Hosp Fdn Jimenez Diaz, START Madrid, Madrid, Spain
[6] Univ Hosp Tubingen, Dept Med Oncol&Pneumol, Tubingen, Germany
[7] Univ Hosp Tubingen, Tubingen Early Phase Clin Trials Unit, Tubingen, Germany
[8] Boehringer Ingelheim Pharmaceut Inc, Global Biostat&Data Sci, Ridgefield, CT USA
[9] Boehringer Ingelheim Pharmaceut Inc, TA Oncol Med, Ridgefield, CT USA
[10] Boehringer Ingelheim Int GmbH, TA Oncol Med, Ingelheim, Germany
[11] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1859
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
673P
引用
收藏
页码：S472 / S473
页数：2
相关论文
共 50 条
  • [21] Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
    Freyer, G.
    Isambert, N.
    You, B.
    Zanetta, S.
    Falandry, C.
    Favier, L.
    Trillet-Lenoir, V.
    Assadourian, S.
    Soussan-Lazard, K.
    Ziti-Ljajic, S.
    Fumoleau, P.
    BRITISH JOURNAL OF CANCER, 2012, 107 (04) : 598 - 603
  • [22] Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
    G Freyer
    N Isambert
    B You
    S Zanetta
    C Falandry
    L Favier
    V Trillet-Lenoir
    S Assadourian
    K Soussan-Lazard
    S Ziti-Ljajic
    P Fumoleau
    British Journal of Cancer, 2012, 107 : 598 - 603
  • [23] A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours
    Gillessen, Silke
    Gnad-Vogt, Ulrike S.
    Gallerani, Elisa
    Beck, Joachim
    Sessa, Cristiana
    Omlin, Aurelius
    Mattiacci, Maria R.
    Liedert, Bernd
    Kramer, Daniel
    Laurent, Julien
    Speiser, Daniel E.
    Stupp, Roger
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (01) : 35 - 44
  • [24] A phase I dose escalation study to assess the safety tolerability and pharmacokinetics of ETS2101 in patients (pts) with advanced solid tumours
    Plummer, R.
    Anthoney, A.
    Evans, J.
    Haris, N.
    D'Archangelo, M.
    Slater, S.
    Campbell, S.
    Brindley, C.
    Self, S.
    McKeown, P.
    Lavin, S.
    Hynes, D.
    Flores, M. V.
    Pedret-Dunn, A.
    Laffranchi, B.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S58 - S59
  • [25] A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
    Diaz-Padilla, I.
    Siu, L. L.
    San Pedro-Salcedo, M.
    Razak, A. R. A.
    Colevas, A. D.
    Shepherd, F. A.
    Leighl, N. B.
    Neal, J. W.
    Thibault, A.
    Liu, L.
    Lisano, J.
    Gao, B.
    Lawson, E. B.
    Wakelee, H. A.
    BRITISH JOURNAL OF CANCER, 2012, 107 (04) : 604 - 611
  • [26] A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
    I Diaz-Padilla
    L L Siu
    M San Pedro-Salcedo
    A R A Razak
    A D Colevas
    F A Shepherd
    N B Leighl
    J W Neal
    A Thibault
    L Liu
    J Lisano
    B Gao
    E B Lawson
    H A Wakelee
    British Journal of Cancer, 2012, 107 : 604 - 611
  • [27] Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escalation/expansion results
    Voskoboynik, M.
    Mileshkin, L.
    Gan, H.
    Millward, M.
    Au-Yeung, G.
    Meniawy, T. M.
    Kichenadasse, G.
    Zhang, K.
    Zhang, M.
    Mu, S.
    Lickliter, J. D.
    ANNALS OF ONCOLOGY, 2019, 30
  • [28] A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
    Schoffski, Patrick
    Awada, Ahmad
    Dumez, Herlinde
    Gil, Thierry
    Bartholomeus, Sylvie
    Wolter, Pascal
    Taton, Martine
    Fritsch, Holger
    Glomb, Patricia
    Munzert, Gerd
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (02) : 179 - 186
  • [29] A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors
    Tolcher, Anthony W.
    Bendell, Johanna C.
    Papadopoulos, Kyriakos P.
    Burris, Howard A.
    Patnaik, Amita
    Fairbrother, Wayne J.
    Wong, Harvey
    Budha, Nageshwar
    Darbonne, Walter C.
    Peale, Franklin
    Mamounas, Michael
    Royer-Joo, Stephanie
    Yu, Ron
    Portera, Chia C.
    Infante, Jeffrey R.
    CLINICAL CANCER RESEARCH, 2016, 22 (18) : 4567 - 4573
  • [30] Phase I dose-escalation trial evaluating the safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors
    Awada, A.
    Gil, T.
    Whenham, N.
    Vanhamme, J.
    Mancini, I.
    Besse, T.
    Brendel, E.
    Loembe, B.
    Piccart, M.
    Hendlisz, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 39 - 39
12345